Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial

PURPOSE: This study aimed to assess the efficacy of utidelone, a novel genetically engineered epothilone analog, combined with capecitabine in our center and, furthermore, to identify whether ganglioside monosialic acid (GM1) improved chemotherapy-induced peripheral neurotoxicity (CIPN). METHODS: Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junnan, Wang, Yan, Jiang, Cui, Cao, Hui, Jiang, Junhan, Xu, Binghe, Sun, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581989/
https://www.ncbi.nlm.nih.gov/pubmed/33163394
http://dx.doi.org/10.3389/fonc.2020.524223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581989/
https://www.ncbi.nlm.nih.gov/pubmed/33163394
http://dx.doi.org/10.3389/fonc.2020.524223

Ejemplares similares